Fairfield, Bush & Co. Seagen Inc. Transaction History

Fairfield, Bush & Co.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.0 - $228.9 $0 - $1.44 Million	-6,279 Reduced 98.59%	90 $20.6 Million
Q3 2023 Nov 15, 2023	SELL	$191.51 - $216.16 $2.49 Million - $2.81 Million	-13,000 Reduced 67.12%	6,369 $1.35 Billion
Q2 2023 Aug 15, 2023	BUY	$187.64 - $206.25 $324,241 - $356,400	1,728 Added 9.8%	19,369 $3.73 Billion
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $1.35 Million - $2.16 Million	10,615 Added 151.08%	17,641 $3.57 Billion
Q4 2022 Feb 14, 2023	SELL	$117.37 - $139.17 $262,439 - $311,184	-2,236 Reduced 24.14%	7,026 $903 Million
Q3 2022 Nov 07, 2022	BUY	$135.27 - $180.11 $217,784 - $289,977	1,610 Added 21.04%	9,262 $1.27 Million
Q2 2022 Aug 09, 2022	SELL	$108.81 - $179.33 $158,644 - $261,463	-1,458 Reduced 16.0%	7,652 $1.35 Million
Q1 2022 May 06, 2022	SELL	$119.61 - $157.85 $58,608 - $77,346	-490 Reduced 5.1%	9,110 $1.31 Million
Q4 2021 Feb 09, 2022	SELL	$142.57 - $190.86 $138,578 - $185,515	-972 Reduced 9.19%	9,600 $1.48 Million
Q3 2021 Nov 08, 2021	BUY	$142.45 - $169.82 $1.51 Million - $1.8 Million	10,572 New	10,572 $1.8 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Fairfield, Bush & Co., based on Form 13F filings with the SEC.

Stay updated on Fairfield, Bush & Co. with notifications on news.